Summary of Baxter's Conference Call Company Overview - **Company**: Baxter International Inc. - **Key Executives**: Joel Grade (CFO), Claire Trackman (SVP, Investor Relations) Core Industry Insights - **Industry**: Healthcare, specifically focusing on medical devices and pharmaceuticals Key Points and Arguments CEO Search Update - The board is making diligent progress in the CEO search, balancing speed and thoroughness [3][4] Growth Strategy - Baxter aims for a growth target of 4% to 5%, driven by innovation and R&D investments [6] - The company is focusing on operational effectiveness and streamlining processes [7] - Inorganic growth opportunities are also part of the strategy, alongside cultural integration [7] Business Identity Post-Sales - Post divestitures (BPS and Vantiv), Baxter is focusing on agility and simplification of operations [11] - The company is emphasizing innovation and capital allocation to drive growth and margin expansion [12] Q1 Performance - Q1 performance exceeded expectations, with a 5% growth driven by strong performance in HST and MPT segments [13][14] - HST grew at a rate of 7%, while frontline care grew by 5% [14] - Notable growth in pump sales and advanced surgeries, although some softness in the U.S. pharma segment [15][16] Q2 Guidance - Q2 guidance is conservative, projecting 1% to 2% growth due to expected conservation in MPT and historical seasonal trends [17][19] - The second quarter is typically the weakest, and hospitals are adjusting back to normal ordering patterns post-allocation [21][24] Pricing Dynamics - Pricing improvements are anticipated, with a full benefit expected in Q2, contributing to a projected 100 basis points improvement for the year [30][31] - The impact of tariffs is being monitored, with China being a significant factor in tariff-related costs [46][47] Margin Expectations - Full-year margin guidance is set at 16% to 16.5%, with expectations for gradual improvement as cost initiatives ramp up [49][52] - TSA income and stranded costs are influencing gross margins, with a focus on operating margins for a clearer profitability picture [65][76] Balance Sheet and Cash Utilization - Baxter is on track to achieve a net debt to EBITDA ratio of three times by year-end, allowing for potential stock buybacks and tuck-in acquisitions [77][78] Additional Important Insights - The company is focusing on maintaining a balanced view across its product lines, particularly in MPT and HST segments [39][42] - There is a recognition of the need for hospitals to return to historical purchasing habits, which may take time [24][28] - The company is committed to exploring small-scale M&A opportunities to enhance growth [78] This summary encapsulates the key insights and strategic directions discussed during Baxter's conference call, highlighting the company's focus on growth, operational efficiency, and financial health.

Summary of LifeStance Health Group (LFST) FY Conference Call - June 10, 2025 Company Overview - LifeStance Health Group is a leader in outpatient mental health services with approximately 7,500 clinicians and over 8 million visits annually across 550 locations in 33 states [4][5][6]. Core Strategies and Management Transition - The management transition from Ken Burdick to Dave Borden as CEO and Ryan McGordy as CFO is expected to be seamless, with a continued focus on clinical and operational excellence [3][9]. - The company aims to maintain a strategy centered on profitable growth, disciplined capital deployment, and enhancing patient and clinician experiences [7][12]. Operational Milestones - Key operational milestones include the rollout of a consistent operating model, a digital patient check-in tool, and improvements in cash collections leading to a positive free cash flow of over $85 million [13][14]. - The company achieved double-digit adjusted EBITDA margins and positive net income for the first time in Q1 2025 [14]. Growth and Hiring Strategy - The clinician base grew by 17% in 2023, with a focus on filling existing clinician schedules rather than solely organic hiring [20][22]. - The company plans to maintain low double-digit clinician growth to support mid-teens revenue growth targets [27][29]. Retention and Competitive Landscape - Despite stable turnover rates, the company is implementing initiatives to improve clinician retention, including changes to payroll frequency and the introduction of cash-based productivity bonuses [34][36]. - LifeStance continues to attract new clinicians, particularly those seeking W-2 benefits and flexible working conditions [40][42]. Financial Performance and Projections - The company anticipates low to mid-single-digit rate increases from payers, with expectations for continued growth in revenue per visit [46][50]. - LifeStance aims for mid-thirties gross margins and 15-20% EBITDA margins in the long term, driven by operational efficiencies and leveraging G&A costs [78][80]. Investment in Technology and Infrastructure - The company is in the early stages of evaluating EHR solutions to enhance clinician and patient experiences, with a decision expected by the end of 2025 [75][76]. - Investments in technology and operational efficiencies are seen as critical for future growth and margin expansion [72][69]. Conclusion - LifeStance Health Group is positioned for continued growth in the outpatient mental health sector, with a strong focus on operational excellence, clinician retention, and strategic investments in technology and infrastructure to support long-term profitability [44][80].

Amneal Pharmaceuticals (AMRX) FY Conference Summary Industry Overview - The generics pharmaceuticals industry is crucial, with 92% of prescriptions filled by generics, referred to as the "affordable medicines group" which includes biosimilars and certain hospital injectables [3][4] - The industry is vital for national security and patient affordability, preventing high costs and shortages [4] Company Vision and Strategy - Amneal Pharmaceuticals aims to expand its core business and focus on biosimilars, targeting to be among the top five players globally in the next five to seven years [5][6] - The biosimilars market presents a significant opportunity, with an estimated annual revenue potential of $500 million to $4 billion from currently underdeveloped molecules [5][6] - The company plans to develop a robust pipeline of 15 to 25 assets annually, emphasizing the complexity of manufacturing and R&D in this space [7] Growth Areas - Amneal is focusing on the GLP-1 diabetes and weight management therapy market, with a significant potential customer base in India, estimated at 55 million people who can afford the therapy [9][10] - The company has secured marketing rights for 20 countries and is positioned as a major supplier for the Metsera product, which is expected to drive growth [8][9] Market Dynamics - The generics market is experiencing typical price erosion of 4-6%, but volume increases from a large portfolio can offset this [15] - The company anticipates a doubling of opportunities in the next five years due to an increase in loss of exclusivity (LOE) products [15][16] - Government incentives are expected to support the affordable medicines industry, leading to growth in both small and large molecule biosimilars [16] Regulatory and Policy Considerations - Amneal is actively lobbying against potential tariffs on the generic industry, arguing that such measures would not bring manufacturing back to the U.S. and could jeopardize national health security [20][22] - The company maintains that 70% of its production value is based in the U.S., which positions it well to handle potential tariff impacts [28] Financial Outlook - The EBITDA margin is currently at 22% and is expected to grow over time, with a focus on maintaining cash generation and reducing leverage [63][99] - Amneal is exploring vertical integration through potential acquisitions, such as Kashiv Bioscience, to enhance its biosimilars business [89][90] Product Development and Launches - The company is confident in the trajectory of its branded products, particularly Crexon, which is expected to achieve peak revenues of $300 million to $500 million [75][81] - Amneal is also preparing to launch a new migraine treatment device, which is anticipated to enhance patient convenience and market presence [85][86] Conclusion - Amneal Pharmaceuticals is strategically positioned to leverage growth in the generics and biosimilars markets, with a strong focus on R&D, partnerships, and navigating regulatory challenges to enhance its market share and financial performance [12][13][31]

Summary of Service Corporation International (SCI) FY Conference Call Company Overview - **Company**: Service Corporation International (SCI) - **Industry**: Funeral services and cemetery offerings - **Position**: Largest owner of funeral homes and cemeteries in North America, with approximately 1,500 funeral homes and 500 cemeteries [6][7] Core Business Model and Strategy - **Market Share**: Funeral business has a market share of about 15%, while the cemetery segment has a market share of approximately 28-30% [7] - **Growth Strategy**: Focus on preneed contracts to capture market share and build a trust fund portfolio [2] - **Earnings Growth**: Historical EPS growth of 8% to 12%, with 5% to 6% from organic growth and 2% to 3% from inorganic growth [9][10] Demographic Trends - **Target Demographic**: Aging baby boomer population, with average ages for funeral services at 82-84 years and cemetery services at around 65 years [8] - **Consumer Behavior**: Shift towards lighter celebrations of life rather than formal services, leading to a transformation in service offerings [8] Financial Performance - **Funeral Volume Trends**: Experienced a spike during the pandemic with an additional 130,000 funerals performed, followed by stabilization and a slight decline in volumes [15][16] - **Revenue per Service**: Steady growth in funeral revenue per service in the low single digits, driven by inflationary price increases and enhanced service offerings [17][20] Preneed Sales - **Preneed Merchandise and Services**: Approximately $2.6 billion in annual sales, with $1.2 billion from funeral services and $1.4 billion from cemetery services [22] - **Backlog**: $16 billion backlog, split between trust funds and life insurance policies, with improved economics due to a recent partnership with Global Atlantic [23][24] Cemetery Segment Insights - **Sales Composition**: Preneed cemetery sales consist of large sales (over $80,000) making up 10-15% of total sales, with core sales being more consistent [27][28] - **Consumer Trends**: Increased interest from baby boomers purchasing adjacent cemetery properties after burying loved ones [29] - **Margin Expansion**: Cemetery segment margins have expanded from 12-13% to 30-35% due to tiered pricing strategies and high-end sales [33][55] Future Outlook - **Growth Projections**: Anticipated return to mid-single-digit growth in preneed cemetery sales as baby boomers continue to influence the market [36] - **EPS Guidance**: Expected EPS growth in the lower end of the 8% to 12% range for 2025, influenced by tax rate changes and stabilization in funeral volumes [58][59] Capital Allocation - **Free Cash Flow**: Projected free cash flow of approximately $550 million, with plans for M&A, construction, dividends, and share repurchases [61][62] Key Takeaways - **Market Position**: SCI is well-positioned to capitalize on demographic trends and has a robust strategy for growth through preneed sales and service innovation [2][8] - **Financial Stability**: Strong cash flow and margin expansion indicate a healthy financial outlook, despite recent fluctuations in funeral volumes [61][55] - **Consumer Relevance**: Continuous adaptation to consumer preferences is crucial for maintaining market share and driving future growth [49][50]

Summary of Performant Healthcare Conference Call Industry Overview - Performant operates in the healthcare payment integrity industry, which is characterized by a limited number of players and a significant market size. The total healthcare spending in the US exceeds $4 trillion, with an estimated $1 trillion wasted, which is more than the entire US K-12 education budget [4][5] - Within this waste, over $300 billion is attributed to payment integrity waste, which relates to the processing of claims [5] Company Positioning and Services - Performant's services are categorized into claims-based and eligibility-based offerings. Claims-based services focus on auditing whether claims should have been paid, while eligibility-based services determine who should pay the claim by coordinating benefits among multiple payers [6] - The company has evolved from a call center debt recovery provider to a healthcare-focused entity since acquiring a CMS contract in 2009. The technology acquired in 2012 remains central to its operations [7] Competitive Landscape - The competitive landscape has consolidated from 10-15 direct competitors to 2-3 major players, enhancing Performant's market position. The industry has seen increased barriers to entry due to the need for compliance and cybersecurity standards [8] - Performant has established strong relationships with federal entities like CMS and five of the top seven national payers, as well as around 20 mid-market plans [9] Growth Strategy - The company's growth strategy includes a "land and expand" approach, where initial contracts lead to upselling additional services over time. This strategy is crucial for expanding relationships with both commercial and government clients [10] - The sales cycle in this industry is lengthy, often taking 2-3 years from contract win to steady revenue, providing high visibility into future results [11] Financial Performance and Projections - For the current year, Performant projects healthcare revenues between $133 million and $135 million, with adjusted EBITDA between $9 million and $10 million. The company aims for a 20%+ adjusted EBITDA margin as it scales [12] - Performant has demonstrated consistent double-digit growth in top-line revenue and anticipates continuing this trend, focusing on execution rather than new market wins [13] Macro Environment and Future Outlook - The company believes it is well-positioned within a macro environment that emphasizes reducing fraud, waste, and abuse in healthcare, which aligns with broader systemic goals [13] - Performant is optimistic about its future, citing a combination of competitive wins and a favorable market environment as key drivers for growth [13] Conclusion - The conference concluded with an invitation for questions, indicating a readiness to engage with stakeholders [14][15]

Summary of Monro (MNRO) FY Conference Call - June 10, 2025 Company Overview - **Company**: Monro, Inc. (MNRO) - **Industry**: Automotive service and tire retail Key Highlights from Quarterly Results - **Comp Store Sales Growth**: Achieved a positive comp store sales growth of **2.8%** adjusted for the previous year's 53-week period [4][5] - **Traffic Trends**: Notable year-over-year increase in traffic starting in March, continuing into April and May [5][6] - **Gross Margin Pressure**: Experienced a **250 basis points** deleverage on gross margin due to extreme weather impacting store traffic and closures [5][6] - **Sales Momentum**: Continued mid-single-digit comp store sales growth in April and May, supported by improved traffic trends [6][10] Management Changes - **New CEO**: Peter Fitzsimmons appointed as CEO, focusing on a performance improvement plan to enhance operations and drive shareholder returns [12][13] - **Leadership Engagement**: Fitzsimmons has been actively engaging with senior leadership and visiting stores to assess opportunities [14][15] Store Closures - **Underperforming Stores**: Announced the closure of **145 underperforming stores**, which represent about **5%** of total sales, equating to approximately **$45 million** in sales reduction for FY 2026 [19][21] - **Closure Costs**: Expected closure costs between **$10 million to $15 million** in Q1 FY 2026 [22] Growth Strategy - **Acquisition Pause**: The company has been on pause regarding acquisitions for the past two years, focusing on internal improvements and operational efficiency [24][26] - **Future Growth**: Plans to leverage improvements for future unit and store location growth, although no specific timeline is set for this growth [26][28] Competitive Landscape - **Fragmented Industry**: The automotive service industry is highly fragmented, with a focus on local consumer experience [29][30] - **Competitive Advantages**: Monro leverages its scale for better pricing and service delivery, investing in technician training and promotional offerings [30][31] Consumer Offering Enhancements - **Tire Assortment Simplification**: Efforts to streamline tire offerings to improve in-store customer experience and operational efficiency [34][36] Tariff Implications - **Cost Increases**: Anticipates cost increases across major product categories due to tariffs, leading to potential price adjustments for consumers [37][38] - **Negotiation Efforts**: Mobilized a team to negotiate with suppliers to mitigate tariff impacts [38][41] Capital Investment and Cash Flow - **Investment Needs**: Capital investments projected between **$25 million to $35 million** for FY 2026, focusing on maintenance and technology projects [43][44] - **Cash Generation**: Expected to generate sufficient cash flow to meet capital allocation priorities, including **$40 million** in finance lease payments and a **$35 million** dividend [46][47] Conclusion - **Short-term Momentum**: The company is experiencing positive momentum and is focused on initiatives to support profitability and sales growth in FY 2026 [48][49]

Summary of Unusual Machines Incorporated Conference Call Company Overview - **Company**: Unusual Machines Incorporated - **Industry**: Drone industry, focusing on small to medium-sized drones and drone parts - **Key Focus**: Manufacturing NDA compliant drone parts outside of China [4][5] Core Points and Arguments - **Revenue Growth**: Achieved a 59% year-over-year revenue increase in Q1, marking every quarter as the best revenue quarter to date [5] - **B2B Business Launch**: Launched B2B operations in September, with revenue increasing 3.5 times from the first half to the second half of the previous year [6][15] - **Financial Position**: Holds $40 million in cash with no debt, and a quarterly operational cash burn of approximately $850,000 [6][24] - **Market Drivers**: The U.S. drone market is being driven by legislation and geopolitical factors, particularly the exclusion of Chinese drones and the conflict in Ukraine [7][20] - **Legislative Support**: Recent laws, including the American Securities Drone Act and the National Defense Authorization Act, are pushing for domestic drone production and limiting Chinese imports [21][22] - **Production Facility**: Signed a lease for a 17,000 square foot drone motor facility, with expectations to deliver motors to customers by late December [8][16] Market Opportunities - **Total Addressable Market (TAM)**: The market for backpack-sized drones in the U.S. is estimated at over $10 billion, especially with the exit of DJI [16] - **Government Contracts**: Anticipates significant government orders for drone systems, potentially amounting to several hundred million dollars [17][30] - **Competitive Positioning**: Positioned in the value segment of the market, offering lower-cost components compared to competitors [18][19] Strategic Initiatives - **Onshoring Strategy**: Plans to accelerate the onshoring of drone parts and components, leveraging relationships with the Defense Innovation Unit (DIU) [11][27] - **Acquisition Strategy**: Open to smart acquisitions as the market consolidates over the next two to three years [12][46] - **Production Capacity**: Aiming to produce 50,000 motors per month, with an estimated run rate of $30 million [37] Financial Outlook - **Break-even Target**: Aiming to reach break-even with an annual revenue of $20 million within four to six quarters [33] - **Revenue Projections**: Expecting a significant ramp-up in revenue following government contract awards, with deliveries anticipated to start in January [32][34] Additional Insights - **Customer Base**: Maintains a diverse customer base with no single customer accounting for more than 5% of revenue [51] - **Community Development**: Observing the formation of drone industry hubs in various U.S. locations, fostering collaboration and innovation [60] - **Supply Chain Resilience**: Emphasizes the importance of a robust domestic supply chain to mitigate risks from geopolitical events and natural disasters [61][62] Conclusion - Unusual Machines Incorporated is strategically positioned to capitalize on the growing U.S. drone market, driven by legislative support and a focus on domestic production. The company is well-funded, with a clear path to growth through B2B initiatives and government contracts, while also addressing supply chain challenges and competitive pricing.

Summary of Sharps Technology Conference Call Company Overview - **Company**: Sharps Technology (STSS) - **Industry**: Specialized drug delivery systems, focusing on safety syringes and prefilled syringes [4][5] Key Points and Arguments - **IPO and Funding**: Sharps Technology went public in April 2022, raising approximately $16 million to acquire a facility in Hungary and commercialize its products [5] - **Acquisition of Safeguard Medical Facility**: The acquisition of a syringe operation in Hungary provided Sharps with its own intellectual property and advanced technology [5][6] - **Sales Agreements**: - A significant $50 million revenue agreement for specialized Sologuard products with a US contract filler in Texas was secured, marking a transformational opportunity for the business [7][20] - Ongoing negotiations for prefilled syringes in South Carolina, although facing some challenges [6][7] - **Manufacturing Plans**: - Plans to scale up manufacturing capabilities in Hungary and South Carolina, with new equipment expected to be operational by Q4 [8][10][22] - The facility in Hungary is fully operational and capable of scaling up to 100,000 square feet, supporting both smart safety syringe technology and prefilled syringe technology [9][10][15] - **Product Development**: - Focus on SecurGuard and Sologuard products, which include advanced safety features and low waste capabilities [11][19] - Prefilled syringes made from copolymer materials are positioned as a high-growth area, offering advantages over traditional glass syringes [12][13][27] - **Market Trends**: - The syringe market is experiencing significant growth, with a shift from glass vials to prefilled syringes, driven by pharmaceutical companies' investments [24][25] - The prefilled syringe market is expected to overtake disposable syringes in the long term [25] - **Competitive Advantage**: - Sharps Technology's products feature low waste technology, which minimizes drug loss during administration, and reuse prevention capabilities, addressing safety concerns [50][51] - The company aims to carve out a niche in the specialty syringe market by leveraging relationships with healthcare providers [42][43] Additional Important Information - **Financial Position**: The company reported a strong cash position of over $11 million with no debt, and a market cap of $6 million [37] - **Future Plans**: Sharps is committed to expanding its prefilled syringe capabilities, with potential announcements expected by the end of the year [36] - **Industry Context**: Competitors like Eli Lilly and Schott are making significant investments in drug filling capabilities, indicating a growing demand for specialized packaging solutions [29][30] This summary encapsulates the key insights from the Sharps Technology conference call, highlighting the company's strategic direction, market opportunities, and competitive positioning within the specialized drug delivery industry.

Broadridge Financial Solutions Conference Summary Company Overview - Broadridge Financial Solutions is a leading provider of technology infrastructure in the financial services industry with a market cap of approximately $28 billion and annual fee revenue of $4.5 billion [3][4] - The company serves clients primarily in wealth management, asset management, capital markets, and corporate issuers, including 28 of the 29 globally systemic important banks [4] Core Business Segments - The Investor Communication Solutions (ICS) unit connects corporate issuers to investors through banks and advisors, facilitating a unique network [5] - The Global Technology Operations (GTO) business includes capital markets and wealth management services, providing front, middle, and back office systems [6][7] Growth Plans - Broadridge's growth strategy focuses on three areas: governance franchise, capital markets, and wealth management modernization [8][9] - The governance franchise aims to democratize and digitize governance, with mid-teens position growth in equities and mid-single digits in funds for FY25 [11][12] - Capital markets are being simplified and innovated, with a focus on AI and new technologies like Bond GPT [13][14] - Wealth management is being modernized through modular solutions, allowing firms to upgrade their back office capabilities [15] Financial Performance - Over the last decade, Broadridge has achieved 10% recurring revenue growth and 13% adjusted EPS growth, with dividends growing in line with earnings [16][17] - The company targets 5-8% organic revenue growth and 8-12% EPS growth over the next three years [17] Market Trends - The democratization of investing is driving position growth, with more investors entering the market and increasing the number of positions per investor [22][23] - Position growth has been in the high single digits over the last decade, with expectations for continued positive trends [25][26] Digital Transformation - Broadridge is actively investing in digital communications, with 85-90% of regulatory communications already suppressed digitally [32] - The customer communications business, valued at $700 million, is transitioning from 85% print to a growing digital segment [38][40] Revenue Streams - Recurring revenue is defined as revenue under contract for multiple years, while event-driven revenue is one-time or sporadic [46][47] - Distribution revenue, primarily from physical output, is expected to grow in the medium term but will likely dissipate in the long term as digital strategies are executed [50][51] Demand and Market Conditions - Demand for solutions related to cost efficiency remains strong, with clients seeking to reduce operational costs [55] - Market volatility has historically not negatively impacted position growth, with strong defensibility observed since 2007 [59][61] Competitive Landscape - Broadridge holds a significant share in the proxy business, with competitors like Proxy Trust and Mediant [66] - The company is exploring growth opportunities in the global proxy business as international investors increasingly buy US securities [66] Regulatory Environment - Current regulations, including potential digital asset disclosures and proxy reforms, are seen as opportunities for Broadridge [68][69] - The company has developed a disclosure solution for digital assets called Clarify [68] Capital Allocation Strategy - Broadridge prioritizes internal growth investments, dividends, tuck-in M&A opportunities, and share buybacks while maintaining an investment-grade credit rating [75][76]

Summary of Ultragenyx Pharmaceutical (RARE) FY Conference Call Company Overview - Ultragenyx Pharmaceutical is at a significant inflection point, achieving revenues between $640 million to $670 million from four products: Crysvita, Nepsevi, Zolcivi, and Evkesa [2][4] - The company is experiencing a global commercial growth rate of approximately 20% annually [2] - Six late-stage programs are in development, with three expected to be filed within the year [4] Pipeline and Product Development - Key late-stage programs include: - Gene therapy for MPS IIIA, currently under review [2] - Gene therapy for GSD I, expected to be filed soon [2] - Osteogenesis Imperfecta (OI) program with high confidence in its transformative potential [5][6] - Angelman syndrome program (ASPIRE study) is on track to complete enrollment by the end of the year [49] - The company aims to become profitable by 2027, leveraging its existing products and new launches [4][68] Clinical Trials and Expectations - The OI program (cetrusumab) shows promising data from phase two trials, with a 67% reduction in fractures [6][19] - A significant threshold for commercial success is expected to be a fracture reduction of over 40%, with hopes for results above 50% [20][21] - The COSMIC trial aims to demonstrate the superiority of cetrusumab over bisphosphonates, which is crucial for market positioning [29][33] Market Strategy and Commercialization - The company plans to focus on key opinion leaders and centers with a high patient volume for initial launches [46] - A field force of 40 to 50 personnel is expected to support the launch, with an emphasis on home infusion models [42][48] - The commercial launch is anticipated to be easier due to a concentrated patient population in clinics [25] Gene Therapy Opportunities - The MPS IIIA program targets a severe disease with a small patient population but high urgency for treatment [59][60] - GSD I has a larger patient population, estimated at 1,500 to 8,000 in the US, with a significant need for treatment [63] - The company believes that urgency and the severity of conditions will drive adoption of gene therapies [66] Financial Outlook - The company reiterated its 2025 revenue guidance, projecting a 14% to 20% year-over-year growth, primarily driven by existing products [67][68] - Approximately 85% of revenue is expected to come from current products, with new launches contributing a smaller portion initially [68][69] Additional Insights - The company emphasizes the importance of patient quality of life and how treatments improve their daily activities, which will be a key driver for adoption [22][24] - Secondary endpoints in clinical trials are considered important for understanding the broader impact of treatments on patients [26][28] This summary encapsulates the key points discussed during the Ultragenyx Pharmaceutical FY Conference Call, highlighting the company's current status, pipeline developments, market strategies, and financial outlook.